Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
ESMO 2024: Risk for Recurrence High for HR-Positive/HER2-Negative High-Risk Node-Negative Early Breast Cancer
Patients with high-risk node-negative disease had 3.2 times higher risk for distant recurrence compared with the overall node-negative population
FRIDAY, Sept. 20, 2024 (HealthDay News) -- Patients with hormone receptor (HR)-positive/HER2-negative high-risk, node-negative (N0) early breast cancer have a considerable risk for recurrence, according to study findings presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.
Komal Jhaveri, M.D., of Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a retrospective study to evaluate risk for recurrence in patients with HR-positive/HER2-negative early breast cancer. The study included patients aged 18 years and older with stage I to III HR-positive/HER2-negative early breast cancer, who were identified by electronic health records. A subgroup of patients with N0 disease with high-risk characteristics was also included. The study included 7,564 patients: 5,557 with N0 disease, 1,560 with N1 disease, and 447 with N2-3 disease.
The researchers found the seven-year incidence of overall recurrence was 7.2% in N0 disease overall, 16.9% in N0 high-risk disease, 17.1% in N1 disease, and 43.7% in N2-3 disease. The seven-year incidence of distant recurrence was 4.3% in N0 disease overall, 13.6% in N0 high-risk disease, 13.7% in N1 disease, and 40.1% in N2-3 disease. The seven-year mortality risk was 11.2%, 16.8%, 15.9%, and 34.9% with N0 disease overall, N0 high-risk disease, N1 disease, and N2-3 disease, respectively.
“This large, retrospective, real-world study demonstrated a clear risk for patients with node-positive and high-risk node-negative disease,” Jhaveri told Elsevier’s PracticeUpdate. “Patients with high-risk node-negative HR-positive/HER2-negative early breast cancer had a 3.2 times higher risk of distant recurrence and a 1.5 times higher risk of mortality at seven years compared with the overall node-negative population, reinforcing that treatments to reduce both the short- and long-term risk of recurrence rates in a broad population of patients with HR-positive/HER2-negative early breast cancer are needed, including those with high-risk, node-negative disease.”